Medy-Tox Inc. (086900.KQ)
KRW 124900.0
(-2.42%)
KRW 124900.0
(-2.42%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 110.88 Billion KRW | 42.72% |
| 2022 | 77.69 Billion KRW | 12.09% |
| 2021 | 69.31 Billion KRW | -36.03% |
| 2020 | 108.35 Billion KRW | 0.3% |
| 2019 | 108.02 Billion KRW | 70.48% |
| 2018 | 63.36 Billion KRW | 8.9% |
| 2017 | 58.18 Billion KRW | 83.89% |
| 2016 | 31.64 Billion KRW | 53.17% |
| 2015 | 20.65 Billion KRW | 24.27% |
| 2014 | 16.62 Billion KRW | -5.92% |
| 2013 | 17.66 Billion KRW | 12.04% |
| 2012 | 15.77 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 33.26 Billion KRW | -7.6% |
| 2024 Q2 | 26.26 Billion KRW | -18.76% |
| 2023 Q2 | 22.39 Billion KRW | 2.6% |
| 2023 FY | 110.88 Billion KRW | 42.72% |
| 2023 Q4 | 36 Billion KRW | 8.48% |
| 2023 Q1 | 21.82 Billion KRW | 18.45% |
| 2023 Q3 | 33.18 Billion KRW | 48.2% |
| 2022 Q3 | 19.51 Billion KRW | -5.22% |
| 2022 FY | 77.69 Billion KRW | 12.09% |
| 2022 Q4 | 18.42 Billion KRW | -5.57% |
| 2022 Q2 | 20.59 Billion KRW | 13.29% |
| 2022 Q1 | 18.17 Billion KRW | 1.48% |
| 2021 FY | 69.31 Billion KRW | -36.03% |
| 2021 Q1 | 19.92 Billion KRW | -53.7% |
| 2021 Q2 | 15.11 Billion KRW | -24.11% |
| 2021 Q3 | 16.35 Billion KRW | 8.2% |
| 2021 Q4 | 17.91 Billion KRW | 9.49% |
| 2020 Q3 | 13.2 Billion KRW | -51.85% |
| 2020 Q4 | 43.02 Billion KRW | 225.72% |
| 2020 FY | 108.35 Billion KRW | 0.3% |
| 2020 Q2 | 27.43 Billion KRW | -3.87% |
| 2020 Q1 | 28.53 Billion KRW | -31.69% |
| 2019 FY | 108.02 Billion KRW | 70.48% |
| 2019 Q1 | 14.59 Billion KRW | 2.1% |
| 2019 Q2 | 25.87 Billion KRW | 77.32% |
| 2019 Q4 | 41.77 Billion KRW | 56.28% |
| 2019 Q3 | 26.72 Billion KRW | 3.32% |
| 2018 Q4 | 14.29 Billion KRW | -13.63% |
| 2018 FY | 63.36 Billion KRW | 8.9% |
| 2018 Q3 | 16.54 Billion KRW | 8.48% |
| 2018 Q2 | 15.25 Billion KRW | -14.93% |
| 2018 Q1 | 17.92 Billion KRW | -7.52% |
| 2017 Q3 | 15.56 Billion KRW | 20.58% |
| 2017 Q1 | 11.16 Billion KRW | 3.72% |
| 2017 Q2 | 12.9 Billion KRW | 15.67% |
| 2017 Q4 | 19.38 Billion KRW | 24.55% |
| 2017 FY | 58.18 Billion KRW | 83.89% |
| 2016 Q4 | 10.76 Billion KRW | 23.68% |
| 2016 Q3 | 8.7 Billion KRW | 31.62% |
| 2016 Q2 | 6.61 Billion KRW | -5.74% |
| 2016 Q1 | 7.01 Billion KRW | 0.86% |
| 2016 FY | 31.64 Billion KRW | 53.17% |
| 2015 Q2 | 3.95 Billion KRW | -28.26% |
| 2015 Q1 | 5.51 Billion KRW | 8.97% |
| 2015 Q4 | 6.95 Billion KRW | 17.21% |
| 2015 Q3 | 5.93 Billion KRW | 49.99% |
| 2015 FY | 20.65 Billion KRW | 24.27% |
| 2014 Q1 | 4.24 Billion KRW | 48.44% |
| 2014 Q4 | 5.05 Billion KRW | 69.2% |
| 2014 Q2 | 4.32 Billion KRW | 1.93% |
| 2014 Q3 | 2.99 Billion KRW | -30.91% |
| 2014 FY | 16.62 Billion KRW | -5.92% |
| 2013 Q2 | 4.86 Billion KRW | -8.38% |
| 2013 Q4 | 2.86 Billion KRW | -38.36% |
| 2013 FY | 17.66 Billion KRW | 12.04% |
| 2013 Q1 | 5.3 Billion KRW | -17.05% |
| 2013 Q3 | 4.64 Billion KRW | -4.55% |
| 2012 FY | 15.77 Billion KRW | 0.0% |
| 2012 Q4 | 6.39 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | -0.817% |
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -1313.304% |
| BINEX Co., Ltd. | 55.67 Billion KRW | -99.163% |
| Bioneer Corporation | 204.55 Billion KRW | 45.793% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | -1332.593% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | -69.771% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | -242.557% |
| Helixmith Co., Ltd | 37.36 Billion KRW | -196.745% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 61.221% |
| Peptron, Inc. | 16.65 Billion KRW | -565.716% |
| Amicogen, Inc. | 52.82 Billion KRW | -109.917% |
| Genexine, Inc. | 41.62 Billion KRW | -166.37% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -585.896% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | -12.437% |
| ALTEOGEN Inc. | 40.93 Billion KRW | -170.879% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | -23.976% |
| SillaJen, Inc. | 5.11 Billion KRW | -2069.014% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | -332.06% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | -214.572% |
| Genomictree Inc. | 16.26 Billion KRW | -581.747% |
| MedPacto, Inc. | 26.91 Billion KRW | -311.916% |
| D&D Pharmatech | 32.16 Billion KRW | -244.758% |
| EASY BIO,Inc. | 29.67 Billion KRW | -273.704% |
| GI Innovation, Inc. | 57.59 Billion KRW | -92.533% |